-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional...
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing...
ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified...
ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing...
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive...
Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and...
-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- ...
ROCKVILLE, Md., March 22, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing...
-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S....
- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - - Strong cash position to...